ATS 2024 Final Program

Click on the session title to view the speakers

8

SATURDAY • MAY 18

Target Audience Nurses, respiratory therapists, pulmonologists/respirologists, postgraduate trainees, inclusive/advanced practitioner, those seeing patients with NTM and bronchiectasis without easy or frequent access to expert guidance. Objectives At the conclusion of this session, the participant will be able to: • understand recent developments in translational and clinical studies related to bronchiectasis and NTM pulmonary disease • review treatment approaches for bronchiectasis, including evolving data on etiologies, exacerbations, and suppressive inhaled antibiotics and macrolides • become familiar with current guideline-based treatment of NTM pulmonary disease The diagnosis and management of bronchiectasis and nontuberculous mycobacteria (NTM) pulmonary infections remains challenging due to a paucity of evidence-based management strategies. There have been recent advances in strategies to suppress and manage bacterial infections such as Pseudomonas aeruginosa in those with bronchiectasis, but treatment of NTM pulmonary disease remains substantially more complex. The most recent ATS/IDSA treatment guidelines for NTM pulmonary disease have aided in this insight. The session will review our current knowledge of bronchiectasis and NTM pulmonary disease epidemiology, environmental sources, etiologies, microbiome, existing and evolving therapies, and 8:05 Epidemiology of Bronchiectasis and NTM 8:35 Species and Sources of NTM Acquisition 8:55 Etiologies of Bronchiectasis 9:20 Bronchiectasis and the Altered Microbiome 9:45 Break 10:15 Airway Clearance Modalities 10:50 Antimicrobial Management in Bronchiectasis: Guideline and Current Data 11:15 Breakout Discussion: Bronchiectasis Cases 12:00 Lunch 1:00 Host Vulnerability and Screening for NTM Infection 1:25 Guideline-Based Therapy: Management of MAC and MAB PD current clinical trials. 8:00 Introduction

1:50 Breakout Discussion: Complex NTM Cases/What to Do When It’s Not MAC or Treatment Isn’t Working 2:35 Break 3:05 Current Clinical Trials/What Is in the Pipeline: NTM 3:30 Current Clinical Trials/What Is in the Pipeline: Bronchiectasis 3:55 Conclusion

CLINICAL • TRANSLATIONAL POSTGRADUATE COURSE

PG9 STATE OF THE ART: LUNG CANCER IN 2024 R Pre-registration and additional fees required. Attendance is limited. Member: $455 In-Training Member: $265 LMIC Member: $320 LMIC In-Training Member: $190 Non-Member: $560 In-Training Non-Member: $395 Assembly on Thoracic Oncology 8:00 a.m. - 4:00 p.m. San Diego Convention Center Room 10 (Upper Level) Target Audience All providers caring for patients with lung nodules/lung cancer (pulmonologist, thoracic surgeons, radiation oncologist, medical oncologist, NP/PA) interested in the translational research being done in this field. Objectives At the conclusion of this session, the participant will be able to: • better counsel patients on lung cancer screening • better utilize biomarkers across the spectrum of lung cancer from early detection to treatment response • better apply recent advances and changes in the treatment of lung cancer to the care of your patients This course will provide a comprehensive review of topics in the evaluation and management of patients with suspected and known lung cancer. We will discuss recent developments in the areas of tobacco control, updated guidelines for pulmonary nodule management and staging for lung cancer, practical tips for lung cancer screening, invasive diagnostic approaches for patients with lung nodules, biomarkers across the spectrum of lung cancer, and updates in immunotherapy for all stages of lung cancer. Attention will be given to the potential disparities in lung cancer screening, diagnosis, and treatment. Interactive tumor

ATS 2024 Conference Program • San Diego, CA